SRPT
Sarepta Therapeutics, Inc.Company Information
- Company Name
- Sarepta Therapeutics, Inc.
- CIK
- CIK0000873303
- Category
- Large accelerated filer
- Ticker: Exchange
- SRPT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- SRPT
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-16
- Last sale
- 2026-03-12
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 22,917
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 105,748,031
- Shares outstanding
- 105,431,000
- Ownership
- 100.30%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 30.95%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 571 | 464 | 801 | 613 | 511 | 241 | 1,103 | 198 | 384 | 427 | 428 | 542 | ||||||
| Short Term Investments | 217 | 189 | 138 | 238 | 290 | 282 | 252 | 1,001 | 1,077 | 963 | 1,248 | 1,192 | ||||||
| Accounts Receivable Net Current | 377 | 395 | 398 | 396 | 527 | 659 | 602 | 435 | 360 | 379 | 400 | 319 | ||||||
| Inventory Net | 904 | 1,001 | 915 | 1,077 | 994 | 941 | 750 | 566 | 486 | 374 | 323 | 244 | ||||||
| Other Assets Current | 106 | 188 | 172 | 192 | 128 | 105 | 90 | 165 | 75 | 83 | 78 | 154 | ||||||
| Assets Current | 2,224 | 2,310 | 2,538 | 2,722 | 2,657 | 2,433 | 3,073 | 2,685 | 2,684 | 2,465 | 2,579 | 2,451 | ||||||
| Property Plant And Equipment Net | 326 | 336 | 345 | 359 | 372 | 361 | 340 | 306 | 276 | 249 | 227 | 212 | ||||||
| Operating Lease Right Of Use Asset | 121 | 124 | 125 | 139 | 143 | 147 | 148 | 141 | 124 | 126 | 130 | 133 | ||||||
| Inventory Noncurrent | 226 | 175 | 185 | 199 | 195 | 181 | 188 | 203 | 205 | 208 | 191 | 176 | ||||||
| Long Term Investments | 145 | 82 | 1 | 1 | 35 | 109 | 133 | 182 | - | - | 0 | - | ||||||
| Other Assets Noncurrent | 146 | 152 | 156 | 73 | 83 | 81 | 80 | 84 | 136 | 176 | 137 | 137 | ||||||
| Assets | 3,189 | 3,179 | 3,350 | 3,493 | 3,680 | 3,465 | 3,963 | 3,600 | 3,424 | 3,224 | 3,265 | 3,110 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 51 | 70 | 281 | 94 | 137 | 156 | 214 | 119 | 107 | 92 | 165 | 88 | ||||||
| Accrued Liabilities Current | 325 | 302 | 360 | 296 | 377 | 392 | 374 | 345 | 350 | 283 | 315 | 322 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 18 | - | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | 36 | - | - | - | - | - | - | - | - | ||||||
| Contract With Customer Liability Current | 110 | 116 | 443 | 485 | 395 | 45 | 130 | 127 | 122 | 112 | 50 | 22 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | 0 | 92 | 92 | 106 | 105 | - | ||||||
| Other Liabilities Current | 17 | 10 | 11 | 10 | 10 | 13 | 13 | 17 | 17 | 16 | 18 | 18 | ||||||
| Liabilities Current | 503 | 499 | 1,095 | 921 | 920 | 606 | 732 | 699 | 688 | 609 | 654 | 451 | ||||||
| Long Term Loans Payable | 848 | 838 | 829 | 1,035 | 1,139 | 1,138 | 1,137 | 1,136 | 1,135 | 1,134 | 1,133 | 1,237 | ||||||
| Operating Lease Liability Noncurrent | 198 | 199 | 199 | 215 | 214 | 205 | 192 | 170 | 144 | 140 | 141 | 135 | ||||||
| Contract With Customer Liability Noncurrent | 110 | 136 | 84 | 0 | 0 | 325 | 325 | 325 | 325 | 325 | 437 | 485 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | 0 | 0 | - | - | 47 | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 7 | 8 | 3 | 0 | ||||||
| Business Combination Contingent Consideration Liability | - | - | 47 | - | 47 | 47 | 47 | 47 | 48 | 48 | 38 | 38 | ||||||
| Liabilities | 1,661 | 1,674 | 2,209 | 2,173 | 2,322 | 2,323 | 2,435 | 2,379 | 2,347 | 2,263 | 2,405 | 2,345 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -25 | -25 | -25 | -25 | -25 | - | 0 | - | - | - | - | - | ||||||
| Additional Paid In Capital Common Stock | 6,105 | 6,077 | 6,043 | 5,987 | 5,844 | 5,801 | 5,739 | 5,589 | 5,482 | 5,372 | 5,305 | 5,257 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | -0 | 0 | -0 | 2 | -1 | -1 | 1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -4,551 | -4,546 | -4,877 | -4,642 | -4,462 | -4,658 | -4,211 | -4,370 | -4,404 | -4,410 | -4,446 | -4,492 | ||||||
| Stockholders Equity | 1,528 | 1,505 | 1,141 | 1,320 | 1,405 | 1,143 | 1,528 | 1,221 | 1,077 | 961 | 859 | 764 | ||||||
| Liabilities And Stockholders Equity | 3,189 | 3,179 | 3,350 | 3,493 | 3,680 | 3,465 | 3,963 | 3,600 | 3,424 | 3,224 | 3,265 | 3,110 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | 198 | ||||||
| Common Stock Shares Issued | 106 | 106 | 106 | 105 | 98 | 98 | 97 | 95 | 95 | 94 | 94 | 94 | ||||||
| Shares Outstanding | 106 | 106 | 105 | 105 | 98 | 98 | 97 | 95 | 95 | 94 | 94 | 94 | ||||||
| Treasury Stock Common Shares | 1 | 1 | 1 | 1 | 1 | - | 0 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSarepta Therapeutics, Inc. (SRPT) — SEC Financial Statements & Analysis
Sarepta Therapeutics, Inc. (SRPT) is a pharmaceutical preparations company, incorporated in DE. Sarepta Therapeutics, Inc. trades on Nasdaq as: SRPT. Sarepta Therapeutics, Inc. (SRPT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Sarepta Therapeutics, Inc. carries a market cap of $1.89B, a P/E ratio of -13.86x, a P/B ratio of 1.24x, a P/S ratio of 1.26x, an enterprise value of $1.31B, and an EV/EBITDA multiple of -13.33x. On profitability, it posts an operating margin of -9.54%, a net margin of -9.11%, a Return on Equity (ROE) of -9.32%, a Return on Assets (ROA) of -3.98%, and a Return on Invested Capital (ROIC) of -15.04%. Per share, it reports EPS of $-1.30, diluted EPS of $-1.30, free cash flow per share of $0.78, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -39.55% year-over-year, net income growth of 135.91% year-over-year, and EPS growth of 119.30% year-over-year. On the balance sheet, it maintains a current ratio of 4.42x, a quick ratio of 2.62x, working capital of $1.72B, a debt-to-equity ratio of 1.09x, a debt ratio of 0.52, free cash flow of $81.85M (TTM), and net debt of $-581.27M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.89B
- P/E TTM
- -13.86x
- EPS TTM
- $-1.30
- P/B TTM
- 1.24x
- ROE TTM
- -9.32%
- ROA TTM
- -3.98%
- Debt To Equity
- 1.09x
- Free Cash Flow TTM
- $81.85M
- Net Revenue TTM Growth 1Y
- -39.55%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Sarepta Therapeutics, Inc. in?
Sarepta Therapeutics, Inc. (SRPT) operates in the Pharmaceutical Preparations industry.
What exchange does SRPT trade on?
Sarepta Therapeutics, Inc. (SRPT) trades on the Nasdaq.
Where is Sarepta Therapeutics, Inc. incorporated?
Sarepta Therapeutics, Inc. is incorporated in DE.
When was Sarepta Therapeutics, Inc. (SRPT)'s most recent SEC filing?
Sarepta Therapeutics, Inc. (SRPT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is SRPT's market cap?
Sarepta Therapeutics, Inc. (SRPT) has a market capitalization of $1.89B as of 2026-06-30.
What is SRPT's EPS (earnings per share)?
Sarepta Therapeutics, Inc. (SRPT)'s trailing twelve month EPS is $-1.30 as of 2026-06-30.
What is SRPT's ROE (return on equity)?
Sarepta Therapeutics, Inc. (SRPT)'s trailing twelve month Return on Equity (ROE) is -9.32% as of 2026-06-30.
What is SRPT's ROA (return on assets)?
Sarepta Therapeutics, Inc. (SRPT)'s trailing twelve month Return on Assets (ROA) is -3.98% as of 2026-06-30.
What is SRPT's ROIC (return on invested capital)?
Sarepta Therapeutics, Inc. (SRPT)'s trailing twelve month Return on Invested Capital (ROIC) is -15.04% as of 2026-06-30.
What is SRPT's EV/EBITDA?
Sarepta Therapeutics, Inc. (SRPT)'s trailing twelve month EV/EBITDA is -13.33x as of 2026-06-30.